||EPS - Basic
||Market Cap (m)
Real-Time news about Neutrahealth (London Stock Exchange): 0 recent articles
|davidosh: RNS Number : 7391Z
28 September 2009
28 September 2009
NEUTRAHEALTH PLC ('the Company')
ISSUE OF SHARE OPTIONS
NeutraHealth plc, one of the leading UK vitamins & supplements companies, today announces that it has re-issued share options to the Executive Directors.
The Board considered that the 9,570,369 share options in issue to the Executive Directors with strike prices of between 10p and 13.5p did not sufficiently incentivise performance in the interests of shareholders, and had unrealistic performance conditions given the current market environment.
The number of options cancelled and reissued for Executive Directors are as follows
Number of cancelled options Strike price Number of reissued options New strike price % of Ordinary Share Capital
10p 5,200,000 4.25p 3.0
Robin Hilton 1,666,666 13.5p 3,666,666
703,703 13.5p 2,703,703 4.25p 1.5
The options detailed above are the only options in issue for the named directors.
The options are exercisable in whole or in part two years after being granted and are subject to a minimum adjusted earnings per share of 1.0p being reached and a minimum share price of 6p per share. Adjusted earnings per share excludes the effect of any significant one off items, share options charges, and amortisation of intangible assets arising on acquisition. The adjustments are detailed in the Annual Report each year. The adjusted earnings per share performance condition does not apply on change of control of the business. The options will lapse if not exercised within ten years of the date of grant. The grant was made on 25 September 2009.
Following the grant of options, the aggregate number of Ordinary Shares under option pursuant to any Company option scheme is within the limit described further in the admission document relating to the re-admission of NeutraHealth to AIM on 31 August 2005 following completion of the acquisition of BioCare Limited. The total number of options over Ordinary Shares which have been granted pursuant to the Company's option schemes is 17,736,773 and the number of new shares issuable pursuant to such options represents 10.1% of the Company's issued Ordinary Share capital. These include options over 1,404,500 Ordinary shares representing 0.8% of the Company's issued Ordinary Share capital which are exempt from the limits described in the admission document referred to above.|
|callumross: Yes, I agree!. However, at least Rensburg Shepherd who have been sellers for months and thereby depressing the share price, are now no longer holders as a result.|
|greedy rooster: If Elder Pharma want to take NUTs home, they need to be bidding 7p minimum. The partial offer to acquire up to 40% more of the equity at or around 5.5p was not welcomed by the shareholders.
Given trading is improving and costs reducing, the price needs to compensate for better fundamentals.
Elder continue to review their options and the share price seems detached from the likely bid outcome.|
|davidosh: The share price has been moving up steadily over the past three months from its lows. Any news ?|
|geovest: Longshanks, I don't think the directors would want an offer from Elder at this stage - they probably want to grow the business, get the share price up and then get a much higher premium from Elder.|
|shammytime: Look at the jump in revenue in the last year - quite staggering.
31-Dec-05 2.42 0.37 0.50p 25.5 n/a n/a n/a 0.0%
31-Dec-06 8.57 0.90 0.50p 17.3 n/a n/a n/a 0.0%
31-Dec-07 21.31 1.86 1.00p 9.8 0.1 +100% n/a 0.0%
EPS growth is 100%. Only a matter of time before the share price rockets here.|
|atlantic53: YEP GREAT LITTLE Company but lousy share price preformance.|
|felix99: I bought some more today too CR. Looks a cracker if Champneys and Travelguard go as expected.
Be an interesting next few months. I have done all the research and if the ranges move well and quick they will shatter EPS forecasts of 1p put out by Daniel Stewart.
If they move slower than expected then first half figs could be a bit dull and this year will be second half weighted.
All looks kosher - hopefully the launch of Champneys stuff will get a good right up in the glossy mags etc and if Posh or someone is seen with the stuff then watch it rocket - and the share price too.
Oh yes and a nice quiet BB - its a cracker I tellya|
|millsig: From Matty's heading:
"With proposed profits expected to grow to £1.6m this year and with such a high rate of growth within the company, a Market Cap of £18m is extremely low. The share price hit 25p when the company had a lot less than they do now."
From the link in post 12:
"The company has released no figures at this time, but for the first half of the year it reported a total turnover of £4.3m (c 6.3m) and operating profit of £0.75m (1.1m).
"Gatto said that NeutraHealth has yet to finish building its base of companies from which it will seek to grow organically, and expects to make two or three more acquisitions in the next couple of years."
OK, comments like "abortive acquisition" and "weak summer" may scare a few off and lack of news tends to increase downward pressure, but market cap is now a mere £11.4m.
Market to book ratio is only 0.85 and one-off costs (see post 11), amount to only £0.35m, compared to cash & securities of £2.28m. Meanwhile, more aquisitions are on the cards.
So, things may get worse before they get better (for the share price), but I hope to top before 28 Feb 2007, as I suspect the results won't be as bad as feared.|
|mattyfromtheblock: NeutraHealth came to the market in February 2005 as a cash shell looking to acquire cash generative companies with positive growth potential. To date they have delivered on exactly what they proposed they would do. In August 2005 they acquired BioCare who are an established developer and distributor of natural healthcare products. In February 2006 they further developed the company by acquiring Nutrigold Limited, which produces a range of nutraceutical products and services for the practitioner market. Both companies are producing a profit and are both fully integrated into the company's Birmingham premises.
The Telegraph rated NUT as a 'Buy' under a month ago saying:
"Diet supplement specialist Neutra-Health's sales are expected to grow from £2.4m last calendar year to £9.3m this year and profit is expected to grow from £400,000 to £1.6m. The nutraceuticals sector is growing by 10 to 15% a year. The company will launch branded travel products into the retail market later this year."
As highlighted in the above paragraph the nutraceuticals sector is growing by 10 to 15% a year. This may well increase as more emphasis is placed on healthy living and vitamin supplementation.
NeutraHealth is successfully implementing its strategy of driving consolidation in the industry by acquiring cornerstone investments and making bolt on acquisitions to these. A recent trading update (layed out below) outlines the company's success and growth prospects.
Exports up 102% year on year (first four months 06) with the majority into
Europe and the Middle East
Initial discussions progressing with new distributors in 5 key European
9 new products launched since December with specific focus on child
Significant UK and overseas distributor interest in the Amanda Hamilton /
Nutrigold Detox range
On-line purchasing website launched with 85% of direct consumer orders new
Appointment of 12 nutritionists nationwide to complement the BioCare
customer development team
The best thing is that although the company is looking to consolidate the market further and gain further market share this way, much of their growth will be organic through realisation of new distributors and increased exports. The fact that 85% of customers who ordered on their new online sales website are completely new customers just goes to show how this company is growing. The website has also only been up for 2 months so this figure will grow without a doubt. It is well layed out and very professional and extremely easy to navigate. The website is:
NeutraHealth's website address is as follows:
With proposed profits expected to grow to £1.6m this year and with such a high rate of growth within the company, a Market Cap of £18m is extremely low. The share price hit 25p when the company had a lot less than they do now. Once it had settled, it still hit 23p. The draw back in price is totally un-founded except for the fact that the company is not on many people's radars yet, but believe me it will be! This could easily get back to 23p and with further consolidation of the sector they will no doubt become a major player. A definite 'Buy and Hold'.|
Neutrahealth share price data is direct from the London Stock Exchange